Tech Company Financing Transactions
ScarX Therapeutics Funding Round
ScarX Therapeutics secured a $2 million Series A funding round on 2/18/2016. Backers included Accel-Rx Health Sciences Accelerator, BDC Venture Capital and MaRS Investment Accelerator Fund.
Transaction Overview
Company Name
Announced On
2/18/2016
Transaction Type
Venture Equity
Amount
$2,000,000
Round
Series A
Proceeds Purpose
With the proceeds, ScarX will complete a Phase I, single-site clinical trial to establish a safety profile for SCX-001 while integrating secondary observational endpoints to provide efficacy signals.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Toronto ON, M4C 1B5
Canada
Toronto ON, M4C 1B5
Canada
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
ScarX Therapeutics (ScarX) is a biotechnology company that discovers and develops innovative treatments for dermal scarring (fibrosis). ScarX's lead candidate, SCX-001, will be the first topical prescription cream to treat and prevent post-surgical scarring.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Operating Officer
Stephen Whitehead
Chief Scientific Officer
Benjamin Alman
President
Parimal Nathwani
Browse more venture capital transactions:
Prev: 2/18/2016: Eqis venture capital transaction
Next: 2/18/2016: Motive Drilling Technologies venture capital transaction
Share this article
News on VC Transactions
We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs